Genetic Predispositions in Peptide Pathways: Context for Personalization Genetic variation in GLP-1 receptor, GIPR, and appetite-related genes may influence how your body responds to GLP-1 therapy
The comparison to FDA-approved alternatives
Carnitine: Sources Foods containing carnitine are usually products of animal origin
SA Medical Journal article Obesity is South Africas new HIV epidemic (Creative Commons Licence) See more from MedicalBrief archives: SAHPRA and drug companies flag risks of compounded weight-loss drugs SAs insulin pens supply dries up as weight-loss drugs take priority Aspen ready to help shrink global shortage of weight-loss drugs Higher Wegovy dose sheds more kilos Novo trial
Oral GLP-1 formulations are adding manufacturing complexity in a different dimension: on December 22, 2025, the FDA approved Novo Nordisk's oral Wegovy 25 mg as the first oral GLP-1 therapy for weight loss, bringing with it the manufacturing requirements of oral solid dosage pharmaceutical production at commercial scale, a fundamentally different infrastructure challenge from parenteral peptide API synthesis
The stomach, outer part of the upper thigh, and the upper arm are the recommended injection sites for subcutaneous administration
)
